共 100 条
[1]
Cambronero J(2013)Profile of lower urinary tract symptoms in the male and their impact on quality of life Actas Urol Esp 37 401-407
[2]
Arlandis S(2012)Consenso sobre el impacto clínico de la nueva evidencia científica disponible sobre hiperplasia benigna prostática Actas Urol Esp 36 265-275
[3]
Errando C(2009)Etiology, epidemiology, and natural history of benign prostatic hyperplasia Urol Clin North Am 36 403-415
[4]
Mora AM(2013)Urine incontinence referral criteria for primary care Aten Primaria 45 263-273
[5]
Cózar-Olmo JM(2005)Consenso sobre terminología y conceptos de la función del tracto urinario inferior Actas Urol Esp 29 16-30
[6]
Hernández-Fenández C(2013)Predictors of successful first-line antimuscarinic monotherapy in men with enlarged prostate and predominant storage symptoms Urology 81 1030-1033
[7]
Miñana-López B(2011)Novel drug targets for the pharmacotherapy of benign prostatic hyperplasia (BPH) Br J Pharmacol 163 891-907
[8]
Amón-Sesmero JH(2008)Use of antimuscarinics in patients with LUTS-BPH and OAB symptoms: clinical expertise and resistance to lose the fear to urinary retention risk Actas Urol Esp 32 957-960
[9]
Montlleó-González M(2015)Drug treatment patterns for the management of men with lower urinary tract symptoms associated with benign prostatic hyperplasia who have both storage and voiding symptoms: a study using the health improvement network UK primary care data Curr Med Res Opin 31 43-50
[10]
Rodríguez-Antolín A(2010)Sociedad Española de Médicos de Atención Primaria; Sociedad Española de Medicina General; Sociedad Española de Medicina de Familia y Comunitaria; Asociación Española de Urología. Referral criteria for benign prostatic hyperplasia in primary care. Sociedad Española de Médicos de Atención Primaria, Sociedad Española de Medicina General, Sociedad Española de Medicina de Familia y Comunitaria, Asociación Española de Urología Actas Urol Esp 34 24-34